New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
07:49 EDTEW, MDTEdwards Lifesciences price target raised to $94-$95 from $90-$91 at Wells Fargo
Wells Fargo increased its price target on Edwards (EW) after the company agreed to settle its litigation with Medtronic (MDT). The firm thinks the terms of the deal were slightly more favorable to Edwards than it had anticipated. It keeps an Outperform rating on Edwards.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
12:35 EDTMDTMedtronic CEO sees Covidien merger closing in early 2015
Subscribe for More Information
07:34 EDTMDTEnteroMedics names Brad Hancock Chief Commercial Officer
Subscribe for More Information
October 28, 2014
11:40 EDTEWEdwards Lifesciences mentioned positively by Navellier
Subscribe for More Information
09:09 EDTMDTMedtronic initiates PERIGON pivotal trial
Subscribe for More Information
07:19 EDTMDTMB Venture Partners to hold a conference
Subscribe for More Information
October 27, 2014
07:23 EDTEWAmerican College of Surgeons holds a conference
Subscribe for More Information
October 24, 2014
12:49 EDTEWOn The Fly: Midday Wrap
Stocks on Wall Street opened relatively quietly, with investors cautious given the way the market closed yesterday following the report a NYC doctor had the Ebola virus. As the morning progressed investors became more emboldened and pushed the market higher, leaving the major averages near their highs at midday. ECONOMIC EVENTS: In the U.S., a report on new home sales showed that they inched up 0.2% to a 467K rate in September, but August was revised much lower. COMPANY NEWS: Shares of Amazon (AMZN) fell 7.5% after the company reported weaker than expected results and provided lower than expected revenue guidance. At least two analysts downgraded the stock following its report, while a number of others cut their price targets on the shares... Procter & Gamble (PG) rose 3% after the company's Q1 core EPS matched estimates and it announced plans to exit the Duracell personal power business. P&G noted that while no decision has been made on the form of the exit, the company’s current preference is a split-off of the Duracell business into a stand-alone company. MAJOR MOVERS: Among the notable gainers was were Edwards Lifesciences (EW), which rose 11% following the company's "beat and raise" report. Also higher was SodaStream (SODA), which jumped 14% after confirming that it has entered into an agreement with PepsiCo (PEP) specifically focused on a small-scale, limited time test to make certain of PepsiCo’s brands available for use on the company’s at-home beverage system. Among the noteworthy losers was Pandora (P), which dropped 15% after reporting quarterly results that included a sequential drop in listener hours. Also lower was Abercrombie & Fitch (ANF), which fell 5.5% after Goldman Sachs downgraded the stock to a Sell rating in a note to investors. INDEXES: Near midday, the Dow was up 86.67, or 0.52%, to 16,764.57, the Nasdaq was up 16.36, or 0.37%, to 4,469.15, and the S&P 500 was up 8.86, or 0.45%, to 1,959.68.
08:37 EDTEWEdwards Lifesciences price target raised to $132 from $100 at Stifel
Stifel increased its price target on Edwards as the firm believes that the company's Q3 results were "outstanding." The firm thinks the TAVR market has a number of very visible and positive global rivers, while the stock has a number of potential positive catalysts. The firm keeps a Buy rating on the shares.
October 23, 2014
16:21 EDTEWEdwards Lifesciences raises FY14 EPS $3.33-$3.39, consensus $3.30
Sees FY 14 revenue higher than previous $2.05B-$2.25B, consensus $2.24B.
16:19 EDTEWEdwards Lifesciences sees Q4 EPS 89c-95c, consensus 95c
Sees Q4 revenue $575M-$615M, consensus $586.91M.
16:15 EDTEWEdwards Lifesciences reports Q3 EPS 80c, consensus 73c
Reports Q3 revenue $607.4M, consensus $546.32M.
15:30 EDTEWNotable companies reporting after market close
Subscribe for More Information
October 22, 2014
07:21 EDTMDTU.S. DHS investigates medical gear for potential cyber defects, Reuters says
Subscribe for More Information
October 21, 2014
09:52 EDTMDTCovidien rises after Medtronic maintains merger date language
Shares of Covidien (COV) are rising in early trading after Medtronic (MDT), in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of the Irish drugmaker, left its language regarding the expected closing date unchanged. WHAT'S NEW: In its most recent filing, Medtronic again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived." ANALYST REACTION: Research firm BTIG says Medtronic's amended regulatory filing on the Covidien transaction increases the firm's confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. WHAT'S NOTABLE: AbbVie (ABBV) last night confirmed that the company and Shire (SHPG), another Irish domiciled drugmaker, agreed to terminate their proposed merger. AbbVie said its decision was based upon its assessment of the September 22 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a "uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions." AbbVie continued that the Treasury notice "introduced an unacceptable level of risk and uncertainty given the magnitude of the proposed changes" and the stated intention of the department to continue to revise tax principles to further impact such "tax inversion" transactions. AbbVie noted that it has agreed to pay Shire a break fee of approximately $1.64B due to the deal falling through. PRICE ACTION: In early trading, shares of Covidien trading in New York rose 4% to $88.86, Medtronic advanced 1% to $64.57, Shires gained 0.7% to $185.82 and AbbVie added 1.4% to $55.16.
09:43 EDTMDTAmended filing increases confidence in Covidien deal at BTIG
BTIG says Medtronic's (MDT) amended regulatory filing on the Covidien (COV) transaction increases its confidence of the deal closing by early 2015. The firm adds it would be "stunned" to see Medtronic walk away from the merger after the company again showed commitment to the acquisition. Shares of Covidien are up 3% to $88.11 in early trading.
09:11 EDTMDTMedtronic keeps language unchanged on merger closing date
Medtronic in its latest regulatory filing answering questions for shareholders regarding its proposed takeover of Covidien (COV) left the language unchanged around the expected closing date. The company again stated, "As of the date of this joint proxy statement/prospectus, the transaction is expected to be completed late in the fourth calendar quarter of 2014 or early 2015. However, no assurance can be provided as to when or if the transaction will be completed. The required vote of Medtronic and Covidien shareholders to adopt the required shareholder proposals at their respective special meetings, as well as the necessary regulatory consents and approvals, must first be obtained and other conditions specified in the conditions appendix must be satisfied or, to the extent applicable, waived."
October 20, 2014
07:20 EDTMDTInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:12 EDTMDTCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use